Mochida Pharmaceutical Co., Ltd. (JP:4534) has released an update.
Mochida Pharmaceutical Co., Ltd. reported a 3.3% increase in net sales for the six months ending September 30, 2024, compared to the same period last year, despite a slight decrease in operating and attributable profits. The company’s equity-to-asset ratio improved to 81.5%, and they maintained their dividend forecast, indicating stable financial performance. Investors may find Mochida’s resilience and consistent dividend policy appealing amidst fluctuating profits.
For further insights into JP:4534 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
